A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.


Journal

Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305

Informations de publication

Date de publication:
Jun 2021
Historique:
revised: 05 12 2020
received: 04 05 2020
accepted: 08 12 2020
pubmed: 29 12 2020
medline: 15 12 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

Standard treatment for naïve hereditary hemochromatosis patients consists of phlebotomy or a personalized erythrocytapheresis. Erythrocytapheresis is more efficient, but infrequently used because of perceived costs and specialized equipment being needed. The main aim of our study was to develop a model that predicts the number of initial treatment procedures for both treatment methods. This information may help the clinician to select the optimal treatment modality for the individual patient. We analyzed retrospective data of 125 newly diagnosed patients (C282Y homozygous), treated either with phlebotomy (n = 54) or erythrocytapheresis (n = 71) until serum ferritin (SF) reached levels ≤100 μg/L. To estimate the required number of treatment procedures multiple linear regression analysis was used for each treatment method separately. The linear regression model with the best predictive quality (R

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Standard treatment for naïve hereditary hemochromatosis patients consists of phlebotomy or a personalized erythrocytapheresis. Erythrocytapheresis is more efficient, but infrequently used because of perceived costs and specialized equipment being needed. The main aim of our study was to develop a model that predicts the number of initial treatment procedures for both treatment methods. This information may help the clinician to select the optimal treatment modality for the individual patient.
METHODS METHODS
We analyzed retrospective data of 125 newly diagnosed patients (C282Y homozygous), treated either with phlebotomy (n = 54) or erythrocytapheresis (n = 71) until serum ferritin (SF) reached levels ≤100 μg/L. To estimate the required number of treatment procedures multiple linear regression analysis was used for each treatment method separately.
RESULTS RESULTS
The linear regression model with the best predictive quality (R

Identifiants

pubmed: 33368569
doi: 10.1002/jca.21867
pmc: PMC8247321
doi:

Banques de données

ClinicalTrials.gov
['NCT00202436']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

340-347

Informations de copyright

© 2020 The Authors. Journal of Clinical Apheresis published by Wiley Periodicals LLC.

Références

J Hepatol. 2010 Jul;53(1):3-22
pubmed: 20471131
Hepatology. 2007 Oct;46(4):1071-80
pubmed: 17828789
Transfusion. 2016 Jan;56(1):261-70
pubmed: 26358375
Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1321-9
pubmed: 23708276
Med Clin (Barc). 2006 Sep 23;127(11):409-12
pubmed: 17020684
Am J Hematol. 1998 May;58(1):16-9
pubmed: 9590143
Z Gastroenterol. 1992 Nov;30(11):779-83
pubmed: 1471384
Br Med J (Clin Res Ed). 1983 Mar 19;286(6369):939
pubmed: 6403144
J Clin Apher. 2021 Jun;36(3):340-347
pubmed: 33368569
J Clin Apher. 2019 Jun;34(3):171-354
pubmed: 31180581
J Clin Apher. 2002;17(2):88-92
pubmed: 12210712
Neth J Med. 2007 Dec;65(11):452-5
pubmed: 18079569
Klin Wochenschr. 1988 May 2;66(9):404-9
pubmed: 3392895
Int J Artif Organs. 1989 Jan;12(1):59-62
pubmed: 2925263
Lancet Haematol. 2017 Dec;4(12):e607-e614
pubmed: 29195602
Transfusion. 2012 Mar;52(3):470-7
pubmed: 21848963
J Clin Apher. 2014 Jun;29(3):133-8
pubmed: 24130064
Gastroenterology. 2010 Aug;139(2):393-408, 408.e1-2
pubmed: 20542038
Blood Transfus. 2014 Jan;12 Suppl 1:s84-9
pubmed: 24333062
Transfus Clin Biol. 2011 Dec;18(5-6):553-8
pubmed: 22019606
Hepatology. 2011 Jul;54(1):328-43
pubmed: 21452290
Blood. 2010 Jul 22;116(3):317-25
pubmed: 20308595
Transfusion. 2011 Jun;51(6):1331-8
pubmed: 21175649
Transfusion. 2015 Mar;55(3):611-22
pubmed: 25209879
Liver Int. 2016 Oct;36(10):1535-9
pubmed: 26992127
Br J Haematol. 2016 Dec;175(5):759-770
pubmed: 27723100
Haematologica. 2005 May;90(5):717-8
pubmed: 15921401
Vox Sang. 2000;79(1):40-5
pubmed: 10971213
Hepatology. 2020 Oct;72(4):1469-1482
pubmed: 32500577

Auteurs

Eva Rombout-Sestrienkova (E)

Department of Transfusion Medicine, Sanquin Blood Supply, Blood Bank Division, Amsterdam, The Netherlands.
Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.

Bjorn Winkens (B)

Department of Methodology and statistics, Maastricht University, Care and Public Health Research Institute (CAPHRI), Maastricht, The Netherlands.

Marian van Kraaij (M)

Department of Transfusion Medicine, Sanquin Blood Supply, Blood Bank Division, Amsterdam, The Netherlands.

Cees Th B M van Deursen (CTBM)

Zuyderland Medical Center, Heerlen, The Netherlands.

Mirian C H Janssen (MCH)

Department of General Internal Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Department of Pediatrics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.

Alexander M J Rennings (AMJ)

Department of General Internal Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.

Dorothea Evers (D)

Department of Immuno-hematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.

Jean-Louis Kerkhoffs (JL)

Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.
Department of Hematology, HAGA Teaching Hospital, The Hague, The Netherlands.

Ad Masclee (A)

Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.

Ger H Koek (GH)

Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH